Dr. Yanyan Lou practices in the department of medical oncology at Mayo Clinic in Jacksonville, FL. There, she treats both lung cancer and mesothelioma. Dr. Lou has particular experience performing immunotherapy and targeted drug therapy treatments, which are both showing much promise as emerging treatments for mesothelioma patients.
Dr. Lou as experience spanning across the past two decades and has accumulated many awards and honors. She is also a member of several prominent medical societies, such as the American Association for Cancer Research and American Society of Clinical Oncology.
Main Specialty: Medical Oncology
Other Interests & Specialties: Lung cancer, mesothelioma, immunotherapy, targeted drug therapy, thymoma, thymic carcinoma, novel investigational therapy in thoracic cancers and translational research in developing novel treatment approaches for thoracic cancers.
Certifications, Awards & Accolades: Eveleigh Family Career Development Award, Jay and Deanie Stein Career Development Award, Young Investigator Award, Merit Award, Postdoctoral Fellow Award, American Society of Clinical Oncology member, American Society of Hematology member, American College of Physicians member, International Society of Biological Therapy of Cancer member, American Association for Cancer Research member
Education & Experience:
- Medical degree from Henan Medical University
- Postdoctoral fellowship in Surgery at NCI, NIH
- Postdoctoral fellowship in Melanoma Medical Oncology at University of Texas MD Anderson Cancer Center
- Residency in Internal Medicine at UT Southwestern Medical School
- Clinical fellowship in Hematology/Oncology at UT MD Anderson Cancer Center
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. Journal for ImmunoTherapy of Cancer. November 2018;6(1):129. doi: 10.1186/s40425-018-0447-2
Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Medicine. October 2018;7(10):4932-4942. doi: 10.1002/cam4.1749
MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics. August 2018;19(1):582. doi: 10.1186/s12864-018-4958-5
The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. Cell Systems. March 2018;6(3):314-328. doi: 10.1016/j.cels.2018.01.013
Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology & Oncology. March 2018;11(1):39. doi: 10.1186/s13045-018-0582-8